PATENT CLAIM ANALYSIS

Application Number: 16042284
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-08
Patent Classification: ["530", "333000"]

Abstract:
The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml. The anti-angiogenic activity analysis illustrates that angiogenesis is arrested when the concentration of antagonistic peptide for VEGF and bFGF is 2000 ng/ml.

Claim (Index 8):
The method according to  claim 1 , wherein antagonistic peptide for vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) comprises amino-acids residues in a range of 5 to 54 amino acids or a segment thereof, and wherein the antagonistic peptide for vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) binds and blocks vascular endothelial growth factor receptors 1 and/or 2 (VEGFR-1 and VEGFR2) and/or basic fibroblast growth factor-receptors 1 and/or 2 (bFGFR-1 arid bFG-FR-2), and wherein the antagonistic peptide for vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) Seq. ID No. 1-Seq. ID No.5 are with or without an additional disulfide bond, and wherein the antagonistic peptide for vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) Seq. ID No. 1-Seq. ID No.5 peptides comprises a plurality of diagnostic, therapeutic and theranosticproperties, and wherein the plurality of diagnostic, therapeutic and theranostic properties of Seq. ID No. 1-Seq. ID No.5 peptides is induced by a plurality of amino acid substitutions and a plurality of different amino acid positions.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 95.0
- Lexical Diversity: 2.75862
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15222237', '10263162', '10046922', '13713594', '13662024']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6437508632879497
- 35 USC 102 Novelty (BERT): 0.5464040374059206
- Combined Prediction Score: 0.6340161806997469
- Mean Citation Score: 381.339348
- Max Citation Score: 398.11826
- Similarity Product: 254.42184305099488

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test